These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27649675)

  • 1. Flavoxate in the symptomatic treatment of overactive bladder: a meta-analysis.
    Sweeney P; Mutambirwa S; Van An N; Sharma JB; Vanamail P
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3703-12. PubMed ID: 27649675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavoxate: present and future.
    Arcaniolo D; Conquy S; Tarcan T
    Eur Rev Med Pharmacol Sci; 2015; 19(5):719-31. PubMed ID: 25807422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavoxate in urogynecology: an old drug revisited.
    Zor M; Aydur E; Dmochowski RR
    Int Urogynecol J; 2015 Jul; 26(7):959-66. PubMed ID: 25480503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.
    Asimakopoulos AD; Cerruto MA; Del Popolo G; La Martina M; Artibani W; Carone R; Finazzi-Agrò E
    Urol Int; 2012; 89(3):259-69. PubMed ID: 22777274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults.
    Roxburgh C; Cook J; Dublin N
    Cochrane Database Syst Rev; 2007 Jul; (3):CD003190. PubMed ID: 17636716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults.
    Roxburgh C; Cook J; Dublin N
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003190. PubMed ID: 17943782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
    Chapple CR; Abrams P; Andersson KE; Radziszewski P; Masuda T; Small M; Kuwayama T; Deacon S
    J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing efficacy endpoints in clinical trials for new oral medicinal treatments for overactive bladder: a systematic literature review and meta-analysis.
    Iino S; Kaneko M; Narukawa M
    Int Urol Nephrol; 2018 Jun; 50(6):1021-1030. PubMed ID: 29651695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [MIRABEGRON--A NEW DRUG FOR TREATMENT OF OVERACTIVE BLADDER].
    Kasjan GR
    Urologiia; 2015; (4):121-4. PubMed ID: 26665779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current pharmacotherapy of overactive bladder in neurological patients].
    Shvarts PG; Vinarov AZ; Kadykov AS; Borodulina IV; Popov SV; Kravchenko MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(12):152-160. PubMed ID: 25741549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.